论文部分内容阅读
目的探讨多西他赛联合顺铂治疗蒽环类耐药性晚期乳腺癌的临床疗效。方法 58例蒽环类耐药性晚期乳腺癌患者作为研究对象,随机分为观察组和对照组,每组29例,其中对照组接受多西他赛治疗,观察组接受多西他赛联合顺铂治疗,对两组的临床效果进行观察,比较和分析两组患者的临床疗效,并对患者进行1年的随访。结果两组患者通过治疗,观察组患者的总有效率为68.95%,对照组患者的总有效率为55.16%,观察组的总有效率优于对照组,差异具有统计学意义(χ2=7.469,P<0.05);观察组患者1年生存率显著高于对照组,差异具有统计学意义(χ2=10.214,P<0.05)。结论在蒽环类耐药性晚期乳腺癌的临床治疗过程中,多西他赛联合顺铂治疗的临床疗效较好,不良反应较低,值得临床推广和使用。
Objective To investigate the clinical efficacy of docetaxel plus cisplatin in the treatment of anthracycline-resistant advanced breast cancer. Methods Fifty-eight patients with anthracycline-resistant advanced breast cancer were randomly divided into observation group and control group, with 29 cases in each group. The control group received docetaxel and the observation group received docetaxel Platinum treatment, the clinical efficacy of two groups were observed, compared and analyzed the clinical efficacy of two groups of patients, and patients were followed up for 1 year. Results The total effective rate was 68.95% in the observation group and 55.16% in the control group. The total effective rate in the observation group was better than that in the control group (χ2 = 7.469, P <0.05). The 1-year survival rate of the observation group was significantly higher than that of the control group (χ2 = 10.214, P <0.05). Conclusion In the clinical treatment of anthracycline-resistant breast cancer, docetaxel combined with cisplatin has better clinical efficacy and lower adverse reactions, which is worthy of clinical promotion and use.